Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer 99mTc-HP-Ark2: a pilot study

Fig. 5

Representative 99mTc-HP-Ark2 SPECT/CT images (transaxial view of SPECT, CT and SPECT/CT fusion), 18F-FDG PET/CT images (transaxial view of PET, CT and PET/CT fusion), and HER2 immunohistochemical (IHC) stains of three patients with breast cancer. A A 33-y-old woman (Patient No. 6) with HER2 (1 +) invasive ductal cancer in her left breast (green arrows), 99mTc-HP-Ark2 tumor-to-background ratio, T/B = 1.00 and 18F-FDG T/B = 11.60. B A 39-y-old woman (Patient No. 1) with HER2 (2 +) invasive lobular cancer in her right breast (brown arrows), 99mTc-HP-Ark2 T/B = 1.64 and 18F-FDG T/B = 15.64. C A 57-y-old woman (Patient No. 26) with HER2 (3 +) invasive ductal cancer in her left breast (red arrows), 99mTc-HP-Ark2 T/B = 4.22 and.18F-FDG T/B = 6.77

Back to article page